A new report based on Montreal research reveals that proton pump inhibitors (PPIs) increase the risk of gastric cancer in users. According to the report, PPIs are more dangerous compared to histamine-2 receptor antagonists (H2RAs). The preceding is the conclusion of a population-based study conducted by researchers at the Lady Davis Institute for Medical Research, Montreal, Canada.
The Montreal research study lasted for five years and covered the follow-up analysis of 973,281 new PPI users and 193,306 new users of H2RAs. The primary purpose was to discover the risk of developing gastric cancer and the number needed to harm (NNH). The secondary analysis assessed the duration and dose-response associations.
Compared to H2RAs, the results showed that the use of PPIs showed a 54 percent increased risk of gastric cancer. It also established an NNH of 2,121 after five years and 1,191 after a 10-year treatment period. Additionally, PPI users recorded a higher cumulative incidence of gastric cancer than H2RA users.
Furthermore, the secondary analysis showed that the hazard rations went up alongside the cumulative omeprazole equivalents and time since treatment initiation. The report noted that these findings are relevant for clinicians, highlighting the need to re-evaluate ongoing treatments constantly. Re-evaluation is primarily essential in patients who use PPI in the long term and without an evidence-based indication for use.
Proton pump inhibitors are medications for treating heartburns, acid reflux, gastroesophageal reflux disease (GERD), and stomach ulcers. However, as effective as PPIs are, several long-term users blamed the drug for kidney disease, kidney injury, kidney failure, and acute interstitial nephritis. The preceding are the basis for several PPI lawsuits in the United States.
Have you suffered an adverse effect from using PPI? Contact our expert mass tort lawyers to find out your legal options.